Clinical Trials Browser

Recruiting × Albumin-Bound Paclitaxel × Breast × Clear all

NCT05422794 2026-03-18

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Phase 1 Recruiting

Triple Negative Breast Neoplasms

NCT07060807 2026-03-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

Breast Neoplasms

NCT06312176 2026-03-13

MK-2870-010

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06841354 2026-03-13

TroFuse-011

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT05325632 2026-03-02

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Phase 2 Recruiting

Breast Neoplasms

NCT07281976 2026-02-12

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms

NCT07394387 2026-02-06

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07284836 2025-12-16

Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy

Phase 2 Recruiting

Hepatic Artery Infusion

NCT05582538 2025-08-24

ATRiBRAVE

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05192798 2025-02-27

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06102824 2024-11-25

ORIENTA

Phase 2 Recruiting

HER2-negative Breast Cancer

NCT05019690 2024-09-19

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Phase 1/2 Recruiting

Advanced Triple Negative Breast Cancer